<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39323594</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1751-1437</ISSN><JournalIssue CitedMedium="Print"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of the Intensive Care Society</Title><ISOAbbreviation>J Intensive Care Soc</ISOAbbreviation></Journal><ArticleTitle>Dynamic dosing for continuous renal replacement therapy: Service evaluation of the safety and effectiveness of titrating dose to biochemistry.</ArticleTitle><Pagination><StartPage>50</StartPage><EndPage>58</EndPage><MedlinePgn>50-58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/17511437231202898</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Continuous renal replacement therapy (CRRT) dose is usually fixed and primarily weight-based. Whilst this is safe, theoretically, underdosing or overdosing may occur in those requiring acute versus maintenance CRRT respectively. We have developed a dynamic dosing protocol for CRRT which individualises and updates dosing according to biochemistry. Here we describe the protocol and compare it to a fixed dose protocol to evaluate its safety and effectiveness.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a service evaluation of this novel protocol using data from consecutive non-COVID-19 admissions receiving CRRT within Barts Health NHS trust, United Kingdom (UK). Fifty admissions using the dynamic protocol were compared to historically collected data from 108 admissions who used the fixed protocol. Acute and maintenance CRRT subgroups were analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">For the dynamic protocol 49 patients were treated with 135 CRRT circuits. One patient had two admissions. Protocol compliance (compared in one ICU) was 76% (dynamic) vs 61% (fixed) (<i>p</i> &lt; 0.05). For the dynamic versus fixed protocol, median CRRT lifespan censored for reasons other than clotting was: 56 h vs 58 h RCA (ns), 27 h versus 20 h heparin (ns) and 79 h versus 22 h no anticoagulation (<i>p</i> &lt; 0.05). The dynamic vs fixed protocol average CRRT dose was: 30 ml/kg/h (14-57) vs 26 ml/kg/h (20-62) (<i>p</i> &lt; 0.05). The dynamic protocol generated a similar rate of increase of bicarbonate in an acute phase (RCA: 0.2 mmol/l/h vs 0.21 mmol/l/h, ns) and maintained a more stable level in a maintenance phase (RCA: -0.01 mmol/l/h vs 0.07 mmol/l/h, <i>p</i> &lt; 0.05).</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Dynamic dosing for CRRT in this institution was safe and may lead to more tailored maintenance of biochemical homoeostasis.</AbstractText><CopyrightInformation>© The Intensive Care Society 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eldridge</LastName><ForeName>Jack C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-6792-7714</Identifier><AffiliationInfo><Affiliation>Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Medicine Research Group, Faculty of Medicine and Dentistry, Queen Mary University, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhardwaj Shah</LastName><ForeName>Aroon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Medicine Research Group, Faculty of Medicine and Dentistry, Queen Mary University, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lucena-Amaro</LastName><ForeName>Susana</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1633-6492</Identifier><AffiliationInfo><Affiliation>Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kirwan</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prowle</LastName><ForeName>John R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0002-5002-2721</Identifier><AffiliationInfo><Affiliation>Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Medicine Research Group, Faculty of Medicine and Dentistry, Queen Mary University, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Yize I</ForeName><Initials>YI</Initials><AffiliationInfo><Affiliation>Adult Critical Care Unit, Royal London Hospital, Barts Health NHS Trust, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Critical Care and Perioperative Medicine Research Group, Faculty of Medicine and Dentistry, Queen Mary University, London, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Intensive Care Soc</MedlineTA><NlmUniqueID>101538668</NlmUniqueID><ISSNLinking>1751-1437</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Continuous renal replacement therapy</Keyword><Keyword MajorTopicYN="N">acid-base balance</Keyword><Keyword MajorTopicYN="N">acute kidney injury</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">renal failure</Keyword></KeywordList><CoiStatement>The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Jack Eldridge, Aroon Bhardwaj Shah, Yize Wan and Susana Lucena-Amaro have no conflicts of interest to declare. Christopher Kirwan has received speaker fees from Baxter Inc, B. Braun Medical Ltd, Fresenius Medical Care and Nikkiso. He has received an unrestricted educational grant from Nikkiso and consultancy fees from Nikkiso and B. Braun Medical Ltd. John Prowle has received hospitality from B. Braun Medical Ltd. and speakers fees from Fresenius Medical Care, Nikkiso Europe GmbH and Baxter Inc. He has performed paid consultancy for Nikkiso Europe GmbH, Baxter Inc and Jafron Biomedical Co Ltd and has received an unrestricted research grant from Jafron Biomedical Co Ltd.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>10</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>4</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39323594</ArticleId><ArticleId IdType="pmc">PMC11421270</ArticleId><ArticleId IdType="doi">10.1177/17511437231202898</ArticleId><ArticleId IdType="pii">10.1177_17511437231202898</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gaudry S, Hajage D, Schortgen F, et al.. Initiation strategies for renal-replacement therapy in the intensive care unit. N Engl J Med 2016; 375: 122–133.</Citation><ArticleIdList><ArticleId IdType="pubmed">27181456</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbar SD, Clere-Jehl R, Bourredjem A, et al.. Timing of renal-replacement therapy in patients with acute kidney injury and sepsis. N Engl J Med 2018; 379: 1431–1442.</Citation><ArticleIdList><ArticleId IdType="pubmed">30304656</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagshaw SM, Wald R, Adhikari NKJ. Timing of initiation of renal-replacement therapy in acute kidney injury. N Engl J Med 2020; 383: 502–251.</Citation><ArticleIdList><ArticleId IdType="pubmed">33113308</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellomo R, Cass A, Cole L, et al.. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627–1638.</Citation><ArticleIdList><ArticleId IdType="pubmed">19846848</ArticleId></ArticleIdList></Reference><Reference><Citation>Palevsky PM, Zhang JH, O’Connor TZ, et al.. Intensity of renal support in critically ill patients with acute kidney injury. N Engl J Med 2008; 359: 7–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2574780</ArticleId><ArticleId IdType="pubmed">18492867</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Gallagher M, Li Q, et al.. Renal replacement therapy intensity for acute kidney injury and recovery to dialysis independence: a systematic review and individual patient data meta-analysis. Nephrol Dial Transplant 2018; 33: 1017–1024.</Citation><ArticleIdList><ArticleId IdType="pubmed">29186517</ArticleId></ArticleIdList></Reference><Reference><Citation>Joannes-Boyau O, Honoré PM, Perez P, et al.. High-volume versus standard-volume haemofiltration for septic shock patients with acute kidney injury (IVOIRE study): a multicentre randomized controlled trial. Intensive Care Med 2013; 39: 1535–1546.</Citation><ArticleIdList><ArticleId IdType="pubmed">23740278</ArticleId></ArticleIdList></Reference><Reference><Citation>Chawla LS, Bellomo R, Bihorac A, et al.. Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup. Nat Rev Nephrol 2017; 13: 241–257.</Citation><ArticleIdList><ArticleId IdType="pubmed">28239173</ArticleId></ArticleIdList></Reference><Reference><Citation>Benichou N, Gaudry S, Dreyfuss D. The artificial kidney induces acute kidney injury: yes. Intensive Care Med 2020; 46: 513–515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224070</ArticleId><ArticleId IdType="pubmed">31832745</ArticleId></ArticleIdList></Reference><Reference><Citation>Neri M, Villa G, Garzotto F, et al.. Nomenclature for renal replacement therapy in acute kidney injury: basic principles. Crit Care 2016; 20: 318.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056503</ArticleId><ArticleId IdType="pubmed">27719682</ArticleId></ArticleIdList></Reference><Reference><Citation>Rewa OG, Villeneuve PM, Lachance P, et al.. Quality indicators of continuous renal replacement therapy (CRRT) care in critically ill patients: a systematic review. Intensive Care Med 2017; 43: 750–763.</Citation><ArticleIdList><ArticleId IdType="pubmed">27730284</ArticleId></ArticleIdList></Reference><Reference><Citation>Gattas DJ, Rajbhandari D, Bradford C, et al.. A randomized controlled trial of regional citrate versus regional heparin anticoagulation for continuous renal replacement therapy in critically ill adults. Crit Care Med 2015; 43: 1622–1629.</Citation><ArticleIdList><ArticleId IdType="pubmed">25853591</ArticleId></ArticleIdList></Reference><Reference><Citation>Schilder L, Nurmohamed SA, Bosch FH, et al.. Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial. Crit Care 2014; 18: 472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4161888</ArticleId><ArticleId IdType="pubmed">25128022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A, Küllmar M, Kindgen-Milles D, et al.. Effect of regional citrate anticoagulation vs systemic heparin anticoagulation during continuous kidney replacement therapy on dialysis filter life span and mortality among critically ill patients with acute kidney injury: a randomized clinical trial. JAMA 2020; 324: 1629–1639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7585036</ArticleId><ArticleId IdType="pubmed">33095849</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolwani AJ, Campbell RC, Stofan BS, et al.. Standard versus high-dose CVVHDF for ICU-related acute renal failure. J Am Soc Nephrol 2008; 19: 1233–1238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2396940</ArticleId><ArticleId IdType="pubmed">18337480</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagshaw SM, Chakravarthi MR, Ricci Z, et al.. Precision continuous renal replacement therapy and solute control. Blood Purif 2016; 42: 238–247.</Citation><ArticleIdList><ArticleId IdType="pubmed">27562079</ArticleId></ArticleIdList></Reference><Reference><Citation>Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 2012; 120: c179–c184.</Citation><ArticleIdList><ArticleId IdType="pubmed">22890468</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostermann M. Editorial: Management of acute kidney injury during critical illness - what is on the horizon? Curr Opin Crit Care 2020; 26: 517–518.</Citation><ArticleIdList><ArticleId IdType="pubmed">33109948</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerdá J, Villa G, Neri M, et al.. Technology in medicine: moving towards precision management of acute kidney injury. Contrib Nephrol 2018; 193: 89–99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29393193</ArticleId></ArticleIdList></Reference><Reference><Citation>Murugan R, Wen X, Keener C, et al.. Associations between intensity of RRT, inflammatory mediators, and outcomes. Clin J Am Soc Nephrol 2015; 10: 926–933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4455205</ArticleId><ArticleId IdType="pubmed">25862777</ArticleId></ArticleIdList></Reference><Reference><Citation>Geerse DA, Bindels AJ, Kuiper MA, et al.. Treatment of hypophosphatemia in the intensive care unit: a review. Crit Care 2010; 14: R147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2945130</ArticleId><ArticleId IdType="pubmed">20682049</ArticleId></ArticleIdList></Reference><Reference><Citation>Klarenbach S, Manns B, Pannu N, et al.. Economic evaluation of continuous renal replacement therapy in acute renal failure. Int J Technol Assess Health Care 2009; 25: 331–338.</Citation><ArticleIdList><ArticleId IdType="pubmed">19619352</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>